Feb 24, 2026Alcohol, Aging, and Long-Term Health: What the Evidence ShowsAlcohol consumption interacts with aging biology in complex ways. This article covers the liver, brain, cardiovascular, and cancer evidence, plus what nutritional strategies can mitigate harm.
Feb 24, 2026Chronic Allergic Inflammation in Aging: Mechanisms and Evidence-Based ManagementAllergic inflammation can worsen with immune senescence, contributing to systemic inflammatory load. This article covers the evidence for dietary and supplement interventions that modulate allergic response without the side effects of antihistamines.
Feb 24, 2026Exercise Recovery in Aging: Why Recovery Slows and Evidence-Based StrategiesRecovery from exercise slows significantly with age, affecting how often and how hard older adults can train. This review covers the biological reasons for prolonged recovery, its consequences for muscle preservation, and evidence-based strategies to support faster, more complete recovery.
Feb 24, 2026Healthcare Access Barriers in Aging: How Financial and Structural Constraints Drive Worse OutcomesCost-related medication nonadherence, missed appointments, and care fragmentation each independently increase hospitalization and mortality in older adults. This article reviews the evidence on access barriers and what interventions actually move outcomes.
Feb 24, 2026Age-Related Hearing Loss: Mechanisms, Cognitive Links, and Nutritional SupportAge-related hearing loss (presbycusis) affects over 60% of adults over 70 and independently accelerates cognitive decline. This article reviews the mechanisms and the limited but growing evidence base for nutritional support.
Feb 24, 2026Heat Stress and Aging: Why Older Adults Are More Vulnerable and How to AdaptThermoregulatory capacity declines with aging: sweating onset is delayed, cardiovascular reserve is reduced, and thirst is blunted. This article covers why older adults face higher heat mortality risk and what evidence supports safe heat adaptation.
Feb 24, 2026Inflammaging: Chronic Low-Grade Inflammation in Aging, Causes, and Intervention EvidenceInflammaging — the chronic low-grade inflammatory state that accumulates with age — is now recognized as a driver of virtually every major age-related disease. Senescent cells, gut dysbiosis, and visceral fat are the primary sources. Targeted interventions address the root causes, not just the biomarkers.
Feb 24, 2026Kidney Health and Aging: GFR Decline, Protein Intake, and Renoprotective StrategiesGFR declines ~1 mL/min/year after age 40. In early-stage CKD, protein restriction, blood pressure control, and avoiding nephrotoxic supplements (high-dose oxalate, aristolochic acid) are the primary levers. Potassium citrate and omega-3 have supportive evidence.
Feb 24, 2026Longevity Biomarkers: What to Track, How Often, and What the Evidence Says They MeanNo single biomarker captures biological age, but a panel of accessible blood and functional markers — HbA1c, hs-CRP, homocysteine, IGF-1, DHEA-S, grip strength, and VO2 max — provides a practical composite picture. Epigenetic clocks offer precision but limited actionability at current cost.
Feb 24, 2026Muscle Power in Aging: Why Force Speed Matters More Than Strength AloneMuscle power — the ability to generate force quickly — declines faster than strength with aging and is a stronger predictor of functional independence and fall risk. This article covers the evidence for power-oriented training and nutritional support.
Feb 24, 2026Nocturnal Blood Pressure Non-Dipping: The Hidden Cardiovascular Risk You Can MeasureBlood pressure normally falls 10–20% during sleep. When this nocturnal dip is absent, cardiovascular and renal risk increase substantially — even if daytime readings appear normal. This article explains the mechanism and evidence-based management strategies.
Feb 24, 2026Orthostatic Intolerance in Aging: Causes, Risks, and Evidence-Based ManagementOrthostatic intolerance — dizziness or near-fainting upon standing — affects up to 20% of adults over 65 and substantially increases fall risk. This article reviews the mechanisms and evidence-based management strategies.
Feb 24, 2026Recurrent UTIs in Aging: Prevention Strategies Beyond AntibioticsRecurrent urinary tract infections are common in older adults, particularly post-menopausal women, and lead to significant antibiotic overuse. This article covers evidence-based prevention strategies including d-mannose, cranberry, and vaginal microbiome support.
Feb 24, 2026SIRT3 and Mitochondrial Integrity: NAD-Dependent Deacetylase, Caloric Restriction Mimicry, and ActivatorsSIRT3 is the primary mitochondrial sirtuin — a NAD-dependent deacetylase that regulates ATP synthesis, ROS detoxification, and fatty acid oxidation. Its activity declines with age and NAD+ depletion. Activators include honokiol, urolithin A, and exercise, though human trial data is thin.
Feb 24, 2026Sleep Architecture in Aging: Why Deep Sleep Declines and How to Partially Restore ItSlow-wave sleep (deep sleep) declines approximately 2% per decade from early adulthood, dropping from roughly 20% of total sleep in young adults to under 5% in adults over 70. This decline is not simply reduced sleep duration — it represents a fundamental change in sleep architecture with consequences for metabolic health, memory consolidation, and cellular repair.
Feb 24, 2026Social Isolation and Loneliness in Aging: The Hidden Health CrisisLoneliness and social isolation are among the strongest independent predictors of cardiovascular disease, cognitive decline, and early mortality in older adults. This article reviews the evidence and practical mitigation strategies.
Feb 24, 2026Sodium-Potassium Balance in Aging: The Dietary Lever for Blood Pressure and Vascular HealthThe ratio of dietary sodium to potassium is a more powerful predictor of cardiovascular risk than sodium intake alone. This article reviews the evidence for the Na/K balance as a therapeutic target and practical approaches to correction.
Feb 24, 2026Testosterone Decline in Aging Men: Natural Interventions, Monitoring, and TRT ContextTestosterone declines ~1% per year after age 30 in men. Below clinical thresholds, symptoms include fatigue, sarcopenia, and cognitive fog. Lifestyle interventions (resistance training, sleep, zinc, vitamin D) have the best evidence for supporting endogenous production. Ashwagandha and fenugreek show modest RCT data.
Feb 24, 2026Tobacco, Smoking, and Aging: Health Damage and Evidence-Based Cessation SupportTobacco is the leading preventable cause of accelerated aging, cardiovascular disease, and cancer. This article covers the biological mechanisms and evidence-based support for cessation and harm mitigation.
Feb 23, 2026Periodontal Disease and Aging: The Overlooked Systemic RiskPeriodontal disease is a chronic inflammatory condition linked to cardiovascular disease, diabetes, and cognitive decline. Here is what the evidence shows about management beyond brushing.
Feb 22, 2026GERD and Acid Reflux in Aging: Mechanisms, Risks, and Evidence-Based ManagementGERD prevalence increases with age and is often overtreated with PPIs, which carry their own risks. This article reviews the mechanisms, evidence-based lifestyle interventions, and where supplements fit.
Feb 21, 2026Dehydration in Aging: Why Thirst Fails and How to Stay Ahead of ItThirst sensitivity declines with age, making chronic underhydration common and underrecognized. This article covers the physiological changes that increase dehydration risk and the evidence-based strategies to counter them.
Feb 21, 2026Gut Microbiome and Probiotics in Aging: Diversity Decline, Leaky Gut, and Evidence-Based InterventionsThe gut microbiome undergoes progressive diversity loss with age — a pattern linked to increased intestinal permeability, systemic inflammation, and reduced short-chain fatty acid production. Dietary fiber, fermented foods, and targeted probiotics have the best evidence for reversing these changes.
Feb 18, 2026Depression and Mood Decline in Aging: Evidence-Based ApproachesLate-life depression is underdiagnosed and undertreated. This article covers the neurobiological drivers of mood decline in aging and the best-evidenced interventions.
Feb 14, 2026Carnosine: Glycation Buffering, Brain Aging, and Carnosinase VariabilityCarnosine is a dipeptide that buffers glycation and carbonyl stress, with additional evidence for neuroprotection. Oral carnosine is cleaved by carnosinase — tissue uptake varies significantly by carnosinase genotype, which affects individual response.
Feb 13, 2026Alpha-Ketoglutarate and Aging: TET Enzyme Activity, Epigenetic Clocks, and Ca-AKG TrialsAlpha-ketoglutarate (AKG) is a TCA cycle intermediate that activates TET enzymes involved in DNA demethylation. The TRIIM-X trial using Ca-AKG reported a reduction in biological age markers. Evidence is preliminary but mechanistically credible.
Feb 13, 2026The Microbiome-Longevity Connection: Centenarian Studies, Gut Diversity, and Prebiotic StrategyCentenarian microbiome studies consistently show higher diversity, more short-chain fatty acid producers, and distinct bacterial profiles compared to age-matched controls. Dietary fiber remains the strongest intervention for diversity. This article maps what the longevity-microbiome evidence shows and what remains speculative.
Feb 11, 2026Age-Specific Supplement Needs: Shifting Priorities from Your 40s to Your 70sSupplement needs shift meaningfully across decades as physiological priorities change. In the 40s, mitochondrial and cardiovascular foundations matter most. In the 50s and 60s, muscle preservation and bone density become critical. In the 70s, anti-inflammatory and immune support take priority.
Feb 11, 2026Circadian Rhythm and Longevity: Disruption Effects, Melatonin, and Timed SupplementationCircadian disruption — from shift work, artificial light, and irregular sleep — accelerates biological aging and increases disease risk. Melatonin, light hygiene, and chronobiologically timed supplement dosing (e.g., resveratrol at night) may partially mitigate disruption effects.
Feb 11, 2026Longevity Gene Activation: SIRT1, AMPK, mTOR, and NRF2 — Compound-by-Compound Evidence MapFour gene networks — SIRT1 (longevity deacetylase), AMPK (energy sensor), mTOR (growth regulator), and NRF2 (antioxidant response) — are the primary longevity targets for supplement intervention. This article maps which compounds activate which genes, the quality of evidence, and where interactions become relevant.
Feb 10, 2026Nicotinamide Riboside and Nicotinamide: NAD+ Precursor Comparison and Human Trial EvidenceNicotinamide riboside (NR) and plain nicotinamide both raise NAD+ but through different pathways and with different safety profiles. NR has more published human trials; nicotinamide is cheaper but raises sirtuin-inhibition concerns at high doses.
Feb 9, 2026Calcium Alpha-Ketoglutarate and Epigenetic Aging: Biological Age Reduction EvidenceCalcium alpha-ketoglutarate (Ca-AKG) is an intermediate in the Krebs cycle and an alpha-ketoglutarate-dependent dioxygenase co-factor critical for epigenetic regulation. A clinical trial showed an 8-year reduction in biological age by DNA methylation clock. Evidence is early but striking.
Feb 9, 2026Epigenetic Clocks and Biological Age: Horvath, GrimAge, DunedinPACE — What They MeasureEpigenetic clocks measure DNA methylation patterns that change predictably with age. Different clocks predict different endpoints — Horvath measures biological age, GrimAge predicts mortality, DunedinPACE measures aging speed. Understanding what they do and don't measure is essential before acting on results.
Feb 9, 2026Gene Therapy for Aging: Telomerase Activation, AAV Delivery, Current Trials, and RisksGene therapy to extend healthspan is moving from animal studies to human trials. Telomerase activation via AAV delivery extended lifespan in mice. Human applications are in early development. The risks — including oncogenic potential — are significant and must be understood clearly.
Feb 8, 2026Epigenetic Reprogramming: Yamanaka Factors, Partial OSK Reprogramming, and the Clinical HorizonPartial epigenetic reprogramming using OSK (Oct4, Sox2, Klf4) Yamanaka factors has reversed multiple aging hallmarks in animal models without inducing cancer. Human translation is in early clinical development. This article explains the biology, current trials, and realistic timeline.
Feb 7, 2026Acarbose and Longevity: ITP Lifespan Data, Postprandial Glucose Control, and Gut Microbiome EffectsAcarbose extended lifespan in male mice more than any other drug in the ITP study. Its alpha-glucosidase inhibition reduces postprandial glucose spikes and feeds colonic bacteria, improving microbiome composition. Human longevity use is off-label and based on mechanistic extrapolation.
Feb 5, 2026Metformin for Longevity: TAME Trial, Off-Label Use in Non-Diabetics, Safety, and ContraindicationsMetformin activates AMPK and has extensive epidemiological longevity data from diabetic populations. The TAME trial will provide the first RCT data for longevity in non-diabetics. Off-label use has meaningful risks including vitamin B12 depletion, GI effects, and contraindications.
Feb 5, 2026mTOR, AMPK, and SIRT1: Longevity Pathway Switches and How Supplements Modulate ThemThree interlocked pathways — mTOR (growth/anabolism), AMPK (energy sensing), and SIRT1 (NAD-dependent deacetylase) — function as master longevity regulators. Supplements like rapamycin, berberine, and NMN modulate them through distinct entry points. Understanding the pathway logic prevents counterproductive stacking.
Feb 4, 2026Resveratrol and SIRT1: Longevity Pathway Activation, Human Trial Disappointments, and ContextResveratrol activated enormous interest as a SIRT1 activator after early animal data. Human trials have been largely disappointing for longevity endpoints. Benefits in specific metabolic contexts (glucose tolerance, inflammation) are more supported. Understanding the gap between mechanism and human outcome is essential.
Feb 3, 2026Fisetin as a Senolytic: Zombie Cell Clearance, Mayo Clinic Data, and Dosing EvidenceFisetin is the most potent natural senolytic identified in preclinical studies. The Mayo Clinic demonstrated senescent cell clearance in human adipose tissue. Clinical protocols use intermittent high-dose cycles. Human evidence is early but promising.
Feb 2, 2026Immune Resilience in Aging: Zinc, Vitamin D, Vitamin C, and Elderberry — Evidence GradientImmunosenescence — the age-related decline in immune function — increases infection risk and reduces vaccine efficacy. Zinc and vitamin D deficiency correction has clear evidence. Vitamin C has moderate support. Elderberry evidence for acute illness is positive but limited for long-term immune maintenance.
Feb 2, 2026Spermidine and Autophagy: Food Sources vs Supplementation, Human Evidence, and Longevity DataSpermidine is the most studied dietary autophagy inducer. Human observational data link higher spermidine intake to reduced all-cause mortality. Supplementation trials are emerging. Wheat germ and other foods provide meaningful amounts but supplements offer dose precision.
Feb 1, 2026Exercise Performance in Aging Adults: Creatine, Citrulline, Beta-Alanine, and What Evidence SupportsOlder adults show a different ergogenic response than younger athletes. Creatine preserves muscle mass and strength. Citrulline improves nitric oxide-dependent exercise capacity. Beta-alanine helps endurance efforts. Protein timing matters more with age.
Feb 1, 2026Rapamycin and mTOR: Longevity Mechanism, PEARL Trial, and Low-Dose Protocol RisksRapamycin extends lifespan in every organism tested and the PEARL trial is the first human RCT for longevity use. mTOR inhibition reduces cellular senescence and improves immune function. Off-label use carries real risks that must be understood before consideration.
Jan 31, 2026NMN vs NR vs Niacin: NAD+ Precursor Comparison, Human Data, and Practical ChoiceNMN and NR both raise NAD+ levels in humans, but mechanistic differences, tissue-specific uptake, and cost vary significantly. Head-to-head human data are limited. This article compares the available evidence and practical considerations for choosing a NAD+ precursor.
Jan 21, 2026Taurine and Aging: Depletion with Age, Cardiovascular Evidence, and Longevity ResearchTaurine levels decline with age and the ICV mouse study showed lifespan extension with supplementation. Human cardiovascular evidence (blood pressure, heart function) is modest but consistent. The longevity case is promising but not yet established in humans.
Jan 15, 2026HMB (Beta-Hydroxy Beta-Methylbutyrate): Muscle Preservation in Aging, Evidence and DosingHMB is a leucine metabolite that reduces muscle protein breakdown. Evidence is strongest in untrained, older, and catabolic populations. Benefits in trained individuals are smaller and less consistent.
Jan 8, 2026Urolithin A and Mitophagy: Direct Supplementation vs Pomegranate, Evidence ReviewUrolithin A is the most clinically studied mitophagy activator in humans. Amazentis trials show improved muscle function and mitochondrial biomarkers in older adults. Diet alone rarely produces adequate levels.